Evaluation of the Efficacy of Sacubitril/Valsartan on Radiofrequency Ablation in Patients with Hypertension and Persistent Atrial Fibrillation

• DOI: 10.1007/s10557-023-07493-6
• Publication Date: 2023-09-07T08:02:27Z
• Authors: Xiaobiao Zang; Zhihan Zhao; Ke Chen; Weifeng Song; Jifang Ma; You Zhou; Erpeng Liang; Haixia Fu; Xianqing Wang; Yonghui Zhao; Rongfeng Zhang

Abstract Objective：To evaluate whether the effect of radiofrequency ablation can be improved by using Sacubitril/Valsartan (S/V) to control blood pressure in hypertensive patients with persistent atrial fibrillation. Methods: A total of 63 and 67 hypertension patients with persistent atrial fibrillation were enrolled in an S/V group and ACEI/ARB group, respectively. All patients underwent radiofrequency ablation (RFCA). The blood pressure of the two groups was controlled within the range of 100–140 mmHg (high pressure) and 60–90 mmHg (low pressure). The clinical indexes of the two groups were observed after 12 months of follow-up. Results: No significant differences in blood pressure were observed between the S/V and ACEI/ARB group. In addition, the recurrence rate of atrial fibrillation between the two groups was not different. The left atrial diameter was an independent predictor of recurrence (HR = 1.063, P = 0.008). However, in the heart failure subgroup, the recurrence rate of S/V was significantly lower than that of the ACEI/ARB group (P = 0.005), and cox regression analysis showed that the recurrence risk of atrial fibrillation of the S/V group was 0.302 lower than that of the ACEI/ARB group. NT ProBNP, LVEF, and LAD were significantly improved in hypertension patients with heart failure when comparing cases before and at the end of follow-up. Conclusions: S/V is better than ACEI/ARB in reducing the recurrence of persistent atrial fibrillation in patients with hypertension and heart failure after RFCA.